Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer

References

• The National Board of Health and Welfare. Cancer Incidence in Sweden 2004. Stockholm: Official Statistics of Sweden; 2005.
   Google Scholar
• The National Board of Health and Welfare. Causes of death 2003. Stockholm: Official Statistics of Sweden; 2005.
   Google Scholar
• Lidgren M, Wilking N, Jönsson B. Cost of breast cancer in Sweden 2002. Eur J Health Econ 2007; 8: 5–15
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235(4785)177–82
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244(4905)707–12
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–92
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005; 23: 4265–74
   PubMed Web of Science ®Google Scholar
• Svenska bröstcancergruppen. Nationellt vårdprogram för bröstcancer. Stockholm; 2003.
   Google Scholar
• Apoteket AB. Apotekens totala försäljning av humanläkemedel 2003–2005. http://www.apoteket.se. Accessed 2006-08-05.
   Google Scholar
• Läkemedelsindustriföreningen. Swedish pharmaceutical reference book. www.fass.se. Accessed August 30th, 2006.
   Google Scholar
• Hornberger J, Kerrigan M, Foutel V. Cost-effectiveness of trastuzumab (herceptin) for treatment of metastatic breast cancer. ESMO Poster 2002.
   Google Scholar
• The National Institute for Clinical Excellence. Guidance on the use of trastuzumab for the treatment of advanced breast cancer - Technology Appraisal Guidance-No.34. London: The National Institute for Clinical Excellence; 2002.
   Google Scholar
• Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol 2004; 22: 854–63
   PubMed Web of Science ®Google Scholar
• Norum J, Risberg T, Olsen JA. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: A model-based cost-effectiveness analysis. Ann Oncol 2005; 16: 909–14
   PubMed Web of Science ®Google Scholar
• Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000; 18: 3651–64
   PubMed Web of Science ®Google Scholar
• Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002; 20: 3095–105
   PubMed Web of Science ®Google Scholar
• Mass R, Press M, Andersson S, Murphy M, Slamon D. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proceedings of ASCO. 2001;20:( Abstract 85).
   Google Scholar
• Vogel CL, Cobleigh M, Tripathy D, Mass R, Murphy M, Stewart SJ. Superior outcome with herceptin (trastuzumab) (H) in Fluorescence in Situ Hybridization (FISH)-Selected Patients. Proceedings of ASCO 2001;20:( Abstract 86).
   Google Scholar
• Press M, Slamon D, Cobleigh M, et al. Improved clinical outcomes for Herceptin treated patients selected by fluorescence in situ hybridization (FISH). Lab Invest 2002:( Abstract 185).
   Google Scholar
• Statistics Sweden. 100 - Life tables. Statistical Yearbook of Sweden 2006. Stockholm: Statistics Sweden; 2005.
   Google Scholar
• Statistics Sweden. Vikt och längd i befolkningen. http://www.scb.se/templates/tableOrChart_47966.asp. Accessed August 30th, 2006.
   Google Scholar
• Lidgren M, Wilking N, Jönsson B, Rehnberg C. Resources use and costs associated with different states of breast cancer. Int J Technol Assess Health Care 2007; 23: 223–31
   PubMed Web of Science ®Google Scholar
• The National Board of Health and Welfare. Vårdkostnader 2002 för NordDRG. http://www.socialstyrelsen.se/NR/rdonlyres/125A3FCE-B0AA-4B9B-ADBF-83533F01CEA2/2857/200412511.pdf. Accessed October 24th, 2006.
   Google Scholar
• Statistics Sweden. 407 - Consumer price index. Statistical Yearbook of Sweden 2006. Stockholm: Statistics Sweden; 2005.
   Google Scholar
• Södra regionsvårdsnämden. Universitetssjukhusen Lund och Malmö. http://www.srvn.org/pris06/26_92.pdf. Accessed October 7th, 2006.
   Google Scholar
• Lidgren M, Wilking N, Jönsson B, Rehnberg C. Health related quality of life in different states of breast cancer. Qual Life Res 2007.
   PubMedGoogle Scholar
• Svenska bröstcancergruppen. Nationellt vårdprogram för bröstcancer. v 1.5:, http://www.swebcg.roc.se/natriklinjbrca.htm. Accessed October 6th, 2006.
   Google Scholar
• Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making 2000; 20: 332–42
   PubMed Web of Science ®Google Scholar
• Persson U, Hjelmgren J. Hälso- och sjukvården behöver kunskap om hur befolkningen värderar hälsan. Läkartidningen 2003; 100: 3436–7
   PubMedGoogle Scholar
• Gold M, Siegel J, Russel L, Wienstein M. Cost-effectiveness in health and medicine. Oxford University Press, New York 1996
   Google Scholar
• Johannesson M. Theory and methods of economic evaluation of health care. Kluwer Academic Publisher. 1996
   Google Scholar
• Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997; 16: 33–64
   PubMed Web of Science ®Google Scholar
• Johannesson M, Meltzer D, O'Conor RM. Incorporating future costs in medical cost-effectiveness analysis: Implications for the cost-effectiveness of the treatment of hypertension. Med Decis Making 1997; 17: 382–9
   PubMed Web of Science ®Google Scholar
• Ekman M, Zethraeus N, Dalström U, Höglund C. Kostnadseffektivt att behandla kronisk hjärtsvikt med bisoprolol. Läkartidningen 2002; 99: 646–50
   PubMedGoogle Scholar
• Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. Pharmacoeconomics. 1996; 9: 113–20
   PubMed Web of Science ®Google Scholar